TCIM
FATE icon

TIAA CREF Investment Management’s Fate Therapeutics FATE Stock Holding History

TIAA CREF Investment Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$1.76M Sell
99,950
-389
-0.4% -$6.14K ﹤0.01% 2066
2018
Q4 		$1.29M Buy
100,339
+7,197
+8% +$100K ﹤0.01% 2188
2018
Q3 		$1.52M Sell
93,142
-4,063
-4% -$48K ﹤0.01% 2253
2018
Q2 		$1.1M Sell
97,205
-5,968
-6% -$65.7K ﹤0.01% 2453
2018
Q1 		$1.01M Buy
103,173
+6,911
+7% +$66.2K ﹤0.01% 2442
2017
Q4 		$588K Sell
96,262
-5,759
-6% -$25.7K ﹤0.01% 2706
2017
Q3 		$404K Sell
102,021
-13,254
-11% -$45.1K ﹤0.01% 2920
2017
Q2 		$373K Buy
+115,275
New +$442K ﹤0.01% 2988

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

TIAA CREF Investment Management's FATE Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its Fate Therapeutics (FATE) stake by 0.39% in Q1 2019, selling an estimated $6.14K and leaving 99,950 shares worth $1.76M. The position accounts for ﹤0.01% of the portfolio, ranked #2066.

TIAA CREF Investment Management first reported a position in FATE in Q2 2017 and has held it in 8 quarters since. 123 funds tracked by Wall St. Rank hold FATE as of Q1 2019.

  • TIAA CREF Investment Management held 99,950 shares of Fate Therapeutics worth $1.76M as of Q1 2019.
  • TIAA CREF Investment Management sold 389 Fate Therapeutics shares in Q1 2019, an estimated $6.14K.
  • Fate Therapeutics made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2066 holding.
  • TIAA CREF Investment Management first reported a position in Fate Therapeutics in Q2 2017 and has held it in 8 quarters since.
  • 123 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.